Medical Oncology

Myeloproliferative Neoplasms   

Questions discussed in this category

Does the anagrelide shortage play a role in your decision-making? Do you avoid anagrelide in general?

In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytore...